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Abstract
Quantitative characterization of the in vivo effects of vascular-targeted therapies on tumor vessels is hampered by the
absence of useful 3D vascular network descriptors aside from microvessel density. In this study, we extended the
quantification of planar vessel distribution to the analysis of vascular volumes by studying the effects of antiangiogenic
(sorafenib and sunitinib) or antivascular (combretastatin A4 phosphate) treatments on the quantity and spatial distributions
of thin microvessels. These observations were restricted to perinecrotic areas of treated human multiple myeloma tumors
xenografted in immunodeficient mice and to microvessels with an approximate cross-sectional area lower than 75 mm2.
Finally, vessel skeletonization minimized artifacts due to possible differential wall staining and allowed a comparison of the
various treatment effects. Antiangiogenic drug treatment reduced the number of vessels of every caliber (at least 2-fold
fewer vessels vs. controls; p,0.001, n = 8) and caused a heterogeneous distribution of the remaining vessels. In contrast, the
effects of combretastatin A4 phosphate mainly appeared to be restricted to a homogeneous reduction in the number of
thin microvessels (not more than 2-fold less vs. controls; p,0.001, n = 8) with marginal effects on spatial distribution.
Unexpectedly, these results also highlighted a strict relationship between microvessel quantity, distribution and cross-
sectional area. Treatment-specific changes in the curves describing this relationship were consistent with the effects
ascribed to the different drugs. This finding suggests that our results can highlight differences among vascular-targeted
therapies, providing hints on the processes underlying sample vascularization together with the detailed characterization of
a pathological vascular tree.
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Introduction
Beginning with the pioneering work of Folkman [1], increasing
attention has been paid to the supportive role played by tumor
vessels in providing proliferating tumor cells with nutriments and
oxygen [2]. Although the complete destruction of the tumor
vasculature cannot yet be achieved, efforts in this direction have
contributed to the development of an increasing number of
vascular-targeted therapies [3]. These therapies are based on
either antiangiogenic drugs, which usually block the development
of new vessels by inhibiting the VEGF pathway [4], or antivascular
agents, which destabilize established vessels causing collapse [5].
Recently, with the discovery of the vasculature normalizing effect
[6,7], it has been shown that antiangiogenic drugs can promote
improved delivery of drugs to tumoral tissues [8,9]. Furthermore,
these results have stimulated the search for combined therapies in
which antiangiogenic and antivascular drugs or conventional
chemotherapies synergize to efficiently destroy the tumor vascu-
lature [10].
Unfortunately, quantification of the efficiency of these therapies
is hampered by the inability to exhaustively describe the
arrangement of a vascular network using a limited number of
efficient parameters. In the last 2 years, efforts aimed at the
unbiased quantitation of vascular beds have resulted in a number
of computer-based utilities addressing planar images or 3D image
stacks. Among these utilities, the CAIMAN [11], AngioTool [12]
and RAVE [13] programs can be used to calculate a number of
parameters related to the quantity and length of vessels. In
addition, these applications can be used to quantitate wall
thickness, branching index values, fractal dimensions and 3D
branch angle. Using a different approach, Kocin´sky and
coworkers [14] proposed that 3D texture analysis is a way to
address and quantify the physical parameters of actual vascular
beds. However, these textural descriptors lack a geometric
interpretation with respect to vascular tree structure. Therefore,
despite these efforts, quantifying vascular characteristics that can
be directly observed, i.e., correlating visual observations with
mathematical values, remains difficult. In this respect, only
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parameters that estimate vessel characteristics, such as mean vessel
density (MVD) [15,16], are widely used to compare the effects of
different in vivo therapeutic approaches in whole tumor nodules.
However, we observed that antiangiogenic drugs affect not only
the total vessel quantity but also their spatial arrangement [17],
which leads to a heterogeneous distribution of vessels in the treated
vascular networks. Building upon this observation, we focused on
thin microvessels with an apparent diameter of less than 10 mm for
2 reasons: first, microvessels ensure the delivery of oxygen and
nutrients throughout the tissue more so than larger vessels [18]
and second, the even distribution of microvessels throughout the
tumor suggests that their presence/absence could signal even small
changes in tumor vascularization. Thus, we investigated whether
tumor vascular trees treated with different vascular-targeted
therapies could be differentiated based solely on the amount,
distribution and caliber of thin microvessels. In this respect we
calculated the 3D spatial dispersion of vessels by assessing the
number of pixel-dilation cycles needed to fill-up a pre-defined
portion (90%) of each vascular volume. This approach, previously
applied to 2D images [17], allowed in this work to discriminate
between homogeneous or clusterized 3D vessel distributions.
Herein, we report that vascular amounts, distributions and calibers
were linked by an evident, although unexpected, relationship. The
shape of the curve describing this relationship appeared to change
according to the treatment applied and provided a graphical and
quantitative characterization of the vascular bed under analysis.
Methods
Ethics Statement
Animal experiments were performed according to Italian law
(D.L. 116/92 and following additions), which enforce the EU 86/
109 Directive, and were approved by the Ethical Committee for
Animal Experimentation of the National Cancer Institute Foun-
dation (Milano, Italy - permit number INT_18_2009). All efforts
were deployed to minimize animal suffering.
Human tumor xenografts, tumor vascularity and necrosis
Six- to eight-week-old female NOD/SCID mice with body
weights of 20 to 25 g were purchased from Charles River (Milano,
Italy, EU). The mice were housed under standard laboratory
conditions according to our institutional guidelines. The human
multiple myeloma KMS-11 cell line [19] was xenografted in
nonobese diabetic/severe combined immunodeficient (NOD/
SCID) mice as previously reported [17,20]. Briefly, KMS-11 cells
(56106 cells/mouse) were inoculated subcutaneously (SC) in the
left flank of each mouse. When tumors were palpable (usually 10–
12 days after tumor inoculation), nodules were already vascular-
ized and showed a diameter of 7–10 mm with a weight of
0.21060.070 g on average. At that time mice were randomly
assigned to receive a 5-day course of either intraperitoneal (IP)
sorafenib (90 mg/kg/day), oral sunitinib (40 mg/kg/day) or a
single IP injection of 50 mg/kg combretastatin-A4-phosphate
(CA4P) 72 hours before euthanasia. In these conditions vessels
were already formed and could be targeted by antivascular agents.
At the same time tumor were still growing, and tumor angiogenesis
was still an active process that could be inhibited by antiangiogenic
agents. Therefore both degree of vascularization and growth rate
of the model were adequate to test antivascular or antiangiogenic
compounds. Treatment protocols were adapted from the literature
[21,22,23] in order to minimize differences in time course and to
analyze all tumors at the same time after implantation. As
reported, we performed a 5-day course treatment for antiangio-
genic drugs whereas we slightly modified CA4P protocols
performing a single injection of 50 mg/Kg CA4P 3 days before
tumor evaluation. In our conditions we could observe necrotic
effects in all samples, proving the action of the drugs, and at the
same time spare still enough viable perinecrotic tissue to allow for
a quantitative description. Efficiency of treatments were tested as
described below and effects illustrated in the Results section.
Vessel walls were biotinylated in vivo through the intravenous
injection of sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-
NHS-LC-biotin, Thermo Fisher Scientific, Rockford, IL, USA) as
previously described [17,20,24]. Biotinylated tumors were then
excised, fixed in 4% paraformaldehyde overnight at 4uC and
embedded in 6% agarose. Agarose-embedded tumors were cut at
a thickness of 100 mm using a vibratome, and the sections were
stained with Alexa Fluor 488-conjugated streptavidin (Invitrogen,
Carlsbad, CA, USA). To evaluate tumor morphology and
necrosis, the same tumor samples were embedded in paraffin,
cut to a 2 mm thickness and stained with hematoxylin and eosin.
The sections were then examined as previously reported [20].
Image sampling, acquisition and pre-processing
For each treatment, images were acquired from samples
obtained from at least 2 independent experiments with at least 2
animals. For each tumor nodule, at least 2 z-series of vascular
fields from 2 different 100 mm-thick sections were acquired using a
MRC-1024 BioRad confocal microscope (BioRad Laboratories
Inc., UK) equipped with a 406oil immersion objective (NA 1.0) at
lambda 488. Pixel dimension was calculated by the accompanying
LaserSharp (BioRad Laboratories Inc., UK) software and resulted
in a size of 0.54 mm. In the vertical axis, slices were 1 mm apart.
The spatial resolution of the system was assessed imaging the sharp
edge of a metal lamina in a fluorescent background. The image
was then used to plot the correspondent Modulation Transfer
Function (Figure 1) [25] using the imageJ program and the
SE_MTF_2xNyquist plugin developed by Mitja et al. (http://
rsbweb.nih.gov/ij/plugins/se-mtf/index.html). After sample ac-
quisition, we converted the resulting 8-bit image stacks to isotropic
stacks using the ImageJ software plug-in "Make Isotropic," which
was developed by Cooper (http://rsbweb.nih.gov/ij/plugins/
make-isotropic/index.html). The image contrast was then en-
hanced using a custom routine that normalized each slice when
the dynamic range of the slice was greater than 30 grey levels.
Finally, the stacks were converted to binary by applying a Renyi
Entropy filter. This algorithm was selected from those available in
ImageJ (http://rsb.info.nih.gov/ij/) because it minimized the
detection of random noise and its results were among the closest
to the thresholds chosen by a trained operator (see Supporting
Information S1).
Voxel classifications according to the size of vascular
cross-sections through Cartesian planes
Binary voxels were assigned to different caliber vascular
components based on their cross-sectional area and according to
the workflow reported in Supporting Information S2. As a first
step, we removed small, isolated particles (cross-sections smaller
than 1 mm2) using an automatic 3D filter based on the TransformJ
package [26], which we implemented as an ImageJ macro. (See
Supporting Information S3). After filling in the hollow vessels, we
classified the resulting voxels according to the minimum dimension
of the cross-sections passing through the voxel that was calculated
for one of the 3 Cartesian planes (see Supporting Information S4).
Finally, these new caliber-filtered vessel maps were intersected
with the input binary volume to obtain the final classification of
input voxels. For each class of projected cross-section, we also
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calculated the volume ascribed to the lumen of hollow vessels by
subtracting the unfilled vessels from the filled volumes.
Surface rendering and vessel skeletonization
Color renderings of treated and untreated vascular networks
were obtained following recovery of the original voxel intensities
by intersecting 8-bit greyscale stacks with the binary volumes of
mapped vessels of a defined caliber. Next, the new images were
color-coded, according to their projected cross-sectional area, as
small (1–5 mm2; cyan), medium (5–19 mm2; yellow) and large (19–
75 mm2; red) and were merged together in a RGB stack. Finally,
we visualized the resulting stack with the ImageJ 3D viewer
rendering tool.
Stack skeletonization was performed using the Skeletonize (2D/
3D) ImageJ plug-in (http://imagejdocu.tudor.lu/doku.
php?id = plugin:morphology:skeletonize3d:start), which was devel-
oped by Arganda-Carreras and based on the decision tree
algorithm created by Lee, et al. [27].
Analysis of percent volume and spatial distribution
The percent volume of a sample was calculated as the ratio of all
black voxels to the total voxels of the volume. Then, to calculate
the spatial distribution, we used a 3D extension of a procedure we
have previously described [17]. According to the original 2D
procedure it is possible to discriminate between homogeneous or
clusterized distributions of pixels in an area. This step is achieved
dilating pixels by mathematical morphology operators until the
expanding surface occupy a pre-defined fraction (usually 90%) of
the area itself. When necessary, a normalization step allows to
compare distributions in equal surfaces showing different amount
of pixels. To this purpose, the pixels in each area are firstly
expanded until they occupy an equal, minimal fraction of the
surface. Then their distribution can be calculated.
In the present work we have adapted this procedure to the 3D
analysis of volumes. Briefly, each volume was filled up to 90% with
expanding black voxels in 3D using a rhombicuboctahedral
dilation (Supporting Information S5), which was obtained by
alternating the mathematical morphology operators 3D-cross and
cuboidal dilation [28]. The final number of dilation cycles needed
to fill exactly 90% of the volume was inferred by linear
interpolation considering the nearest results encompassing this
value. This number was dubbed volumetric Halo index (Hv) by
analogy with the planar Halo index we already described [17]. For
each analysis, the greatest initial volume observed among all of the
volumes to be analyzed was used as the normalization value. In
this respect, for each sample, the number of initial dilation cycles
needed to reach the normalization value was subtracted from the
total number of cycles needed to fill 90% of the volume to give a
normalized, volumetric Halo index (nHv). According to the
protocol of analysis, higher nHv numbers correlated with poorer
volume-filling layouts, i.e. more clusterized distributions. This
approach was implemented both as an ImageJ plugin and as a
macro and was validated against artificial and real voxel
distributions (Supporting Information S6).
Software and statistical analyses
The main ImageJ scripts used in this study and the ImageJ
plugin are provided as supplementary information files together
with instructions for use (Supporting Information S7). Document
Supporting Information S8 details the code for a 3D filter (needs
the TransformJ package [26]). Document Supporting Information
S9 present the source of the macro performing voxel classification
according to the minimal Cartesian surface to which they belong.
For spatial dispersion refer to documents Supporting Information
S10 (source code of plugin) or Supporting Information S11
(macro). Routines can be tested with data from file Supporting
Information S12 which contains 2 images referring to a control
tumor stack at different steps during processing. ImageJ routines
and all images of tumor vessels, both treated or not, have also been
deposited in the Dryad repository ’http://dx.doi.org/10.5061/
dryad.6c44q’.
Analyses and tests were performed using the R software
environment [29] and its basic statistical package. In descriptive
statistics, medians were preferred to mean values because they are
more robust statistical indicators. Bivariate data dispersion around
the median values was generally indicated with the 25–75%
interquartile range because the distribution of the nHv values
diverged from normality. All data obtained from automatic
routines are reported in spreadsheets Supporting Information
S13 and Supporting Information S14 for reader’s convenience.
Curve fitting and the relative coefficient of determination (R2)
were obtained using the curve fitter tool in ImageJ.
Results
Effects of vascular-targeted therapies
As a preliminary control, we evaluated whether the three drugs
used in this study, including the antiangiogenic agents sorafenib
[30] and sunitinib [31,32] and the vascular-disrupting agent CA4P
[33,34], caused a significant increase in the number of necrotic
areas in KMS-11 tumor nodules (Figure 2) as compared to
controls. In particular, sorafenib and sunitinib caused widespread
and scattered areas of necrosis within tumor nodules and a strong
reduction in tumor vascularization [30,32]. In contrast, CA4P-
treated tumors presented massive necrotic areas associated with
hemorrhagic spots and congested and coagulated vessels [33].
Identification of microvessels and classification according
to cross-section
We identified vessel walls by applying the Renyi Entropy
threshold algorithm to isotropic, contrast-enhanced, grey-scale
stacks acquired from sulfo-biotin-stained samples. This simple
approach provided clean volumes devoid of random noise but
other procedures can be used to obtain binary representations of
tumor vessel networks [35]. For each binary volume, identified
voxels were divided among several stacks in agreement with the
approximate cross-sectional area of the microvessel they repre-
sented. However, to address the presence of voxels that belonged
to a vessel but were not connected to it, we assigned voxels to
Figure 1. Spatial resolution of the acquisition system. The plot
of the modulation transfer factor was obtained after imaging of a sharp
edge. The stippled line highlights the maximal contrast obtainable at a
spatial frequency of 1 mm21 (0.54 cycles/pixel). The curve reports the
feasibility to resolve details up to micrometric precision.
doi:10.1371/journal.pone.0059691.g001
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vessels according to a reconstructed map of filled microvessels
(Supporting Information S2 and S4) rather than considering voxels
aside from their context.
Microvessels, which demonstrated approximate cross-sectional
areas ranging from 1 to 75 mm2 (less than 10 mm diameters for
cylindrical vessels), were classified using 4 redundant sets of bins in
geometric sequence (measures in mm2). First set 1–2, 2–5, 5–9, 9–
19, 19–37, 37–75 see Table 1, second set 1–3, 3–6, 6–12, 12–23,
23–47, third set 2–3, 3–7, 7–14, 14–28, 28–56 fourth set 2–4, 4–8,
8–16, 16–33, 33–65. This choice reflected our desire to use a large
number of classes without increasing misclassification due to poor
bin size. In fact, under the conditions applied, the measure of the
cross-sectional surface S of a vessel could not be precisely assessed
from the value of its minimal projection on Cartesian planes (P).
Depending from vessel orientation, S could range from P to P!2
increasing unreliability of classification along with reduction in bin
size. An example of the results of the classification process is shown
in Figure 3 using the set of bins from Table 1 on the vessels shown
in panel A. As an additional effect, the procedure efficiently
removed vessels with cross-sections larger than the upper limit of
the set (arrowheads in panel 3A).
An unexpected relationship links the amount, dispersion
and caliber of microvessels
For all of the classes that were used to divide the vascular
components of the analyzed vascular networks, we calculated the
percent of voxels (V%) and a normalized volumetric Halo value
(nHv) reflecting the spatial distribution of the voxels themselves.
An analysis of the stacks derived from untreated KMS-11
nodules is shown in Figure 4 as a z-projection of a 3D plot with the
classes of vessels ordered along the z-axis and the values for V%
and nHv oriented along the abscissa and the ordinate, respectively.
Surprisingly, the points resulting from the analysis were mainly
organized in monotonic sequences (Figure 4A) and were neither
scattered all over the plot nor grouped in a restricted area. This
organization was confirmed for each sample by fitting all of the
points with a 2nd degree polynomial curve. The goodness of fit was
confirmed according to the values of the coefficient of determi-
nation (R2), which was consistently greater than 0.93 and was even
greater than 0.98 for 7 of the 8 curves. Thus, these findings
demonstrated the existence of an unexpected relationship between
vessel wall quantity, spatial distribution and caliber. Interestingly,
the results from the analysis of vessels that were classified as a
single set of non-overlapping classes (Figure 4B) were sufficient to
approximate the organization of all of the points in the plot, which
eliminated the need to classify vessels in a redundant way.
Consequently, the remaining results were collected from vessels
that were classified using only the first set of bins, as reported in
Table 1.
Vascular-targeted therapies alter the relationship
between microvessel quantity, distribution and caliber
The analysis performed on the controls was repeated on tumors
treated with vascular-targeted drugs, including the antiangiogenic
agents sorafenib [30] and sunitinib [31,32] and the vascular-
disrupting agent CA4P [33,34]. Figure 5A to D shows still images
Figure 2. Effects of antiangiogenic and antivascular treatments on KMS-11 tumor nodules. Panel A. Biotinylated tumor samples for 3D
vascular analysis were embedded in paraffin, cut to a 2 mm thickness and stained with hematoxylin and eosin to reveal necrotic areas. Representative
images are shown. Objective lens, original magnification: 0.08 NA dry objective, 26 and 0.4 NA dry objective, 10x. N, necrosis; V, viable cells; H,
haemorrhagic areas. Arrows indicate congested vessels. Panel B. Biotinylated vessels were revealed by staining sections with Alexa Fluor 488-
conjugated streptavidin. Representative 2D images of tumor samples for 3D vascular analysis are shown. Objective lens, original magnification: 1.0
NA oil objective, 40x.
doi:10.1371/journal.pone.0059691.g002
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from color renderings of the vascular networks in the analysis to
highlight differences in network organization. In addition,
Figure 5E reveals the results of the analyses, as shown as a z-
projection of the plot between the projected cross-sectional values
and the values of V% and nHv.
All vascular-targeted therapies induced changes with respect to
the controls, and these changes were markedly evident for the
antiangiogenic agents that caused a general reduction in the
quantity of vessels and a corresponding heterogeneous distribution
of the vessels. Moreover, this effect increased with increasing vessel
cross-sectional areas and reached a maximum effect for the
thickest microvessels examined.
In contrast, when tumors were treated with the antivascular
drug CA4P, only thin microvessels appeared to show a reduction
in percent volume and space-filling values. Thus, these findings
demonstrated the specific actions of each of the 3 therapies
applied.
Removing effects due to wall staining
To allow for an improved comparison between the effects of
different therapies, we removed variability due to treatment-
specific changes in vessel staining. To do so, filled vessels were
reduced to their basic skeletons using the ImageJ plug-in
Skeletonize (2D/3D). Skeletonized voxels could then be classified
into different stacks according to the size of the cross-section,
which was calculated on the vascular maps that were previously
used to classify input voxels.
An analysis of the volume and distribution of skeletonized
vessels is reported in Figure 5F. Under these new conditions,
vessels treated with sorafenib or sunitinib produced similar values,
which were markedly different from the controls. Similarly, results
obtained from CA4P-treated vessels mapped to a different area of
the plot with respect to the controls and vessels treated with
antiangiogenic drugs. Spatial differences were tested for statistical
significance using Welch’s 2-tailed t-test and Wilcoxon rank tests,
and the results are shown in Table 2. With respect to the controls,
the loss of vessels induced by CA4P consistently appeared
Figure 3. Example of vessel classification according to the approximate size of the cross-section. A. Surface rendering of an 8-bit stack
representing a vascular bed from an untreated KMS-11 nodule. B to G. Surface renderings of filtered vessels classified using the first set of bins listed
in Table 1. Vascular components were arbitrarily color-coded, according to their cross-sectional area, as small (1–5 mm2; cyan), medium (5–19 mm2;
yellow) and large (19–75 mm2; red) H. Surface rendering of the reconstituted organization of filtered vessels; the volumes of B to G were summed
while preserving their colors. Arrowheads in panel A point to vessels efficiently removed from panel H due to exceedingly large cross-sections.
doi:10.1371/journal.pone.0059691.g003
Table 1. Details of vessel classification.
Lower limit - Upper limit (px) Projected vessel cross-section ( mm2) Symbols
4 – 8 1 – 2 Open diamond
8 – 16 2 – 5 Closed diamond
16 – 32 5 – 9 Open triangle
32 – 64 9 – 19 Closed triangle
64 – 128 19 – 37 Open circle
128 – 256 37 – 75 Closed circle
The table reports the parameters and limits (pixels) of the first set of bins used to classify vessels, as well as the value range of the projected relative cross-sections. In
addition column 3 lists the symbols used to indicate the relative results plotted in Figures 4, 5 and 6.
doi:10.1371/journal.pone.0059691.t001
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significant (p,0.05), as significant changes were observed regard-
ing the spatial distribution of vessels in sections with cross-sectional
areas as large as 19 mm2. In contrast, nearly all of the differences
observed between the controls and sorafenib- or sunitinb-treated
samples were highly significant (p,0.001), both in volume and
spatial distribution.
Exclusion of possible artifacts induced by CA4P
treatment
Vascular-disrupting agents (VDA) may alter the apparent
dimension of vessels after sulfo-biotin staining as a consequence
of dye uptake by damaged endothelial cells [33,36]. To evaluate
this possibility, which could artificially alter the results even after
skeletonization, we followed 3 different approaches. First, remem-
bering that input voxels were obtained after image thresholding by
removing very small particles (see Figure S2), we assessed the ratio
between the amount of input voxels and the amount of
skeletonized voxels. Given that the number of skeletonized voxels
is influenced by the length of the vessels, this ratio was roughly the
average amount of sulfo-biotin binding per unit of vessel length.
Treatments should not alter this value; however, in the event of
dye uptake by cells we expected a marked increase because of
apparently thicker cell walls. Figure 6A shows that treatment with
CA4P increased this value less than treatments with sorafenib and
sunitinib, although the overall effect was marginal and observed
only for the largest vessels.
Next, we assessed the ratio between the total luminal volume of
the vessels and the corresponding quantity of the input voxels
(Figure 6B). This parameter is inversely related to wall thickness
and in the case of artefactual cell staining we expected a drop in its
value. However, data indicated that CA4P samples presented
similar results as untreated nodules for most classes of cross-section
with only a slight reduction for large vessels. Samples treated with
sorafenib behaved as controls whereas vessels treated with
sunitinib presented a significant increase (p,0.05, n = 8) in this
ratio when vessels with cross-sectional areas greater than 2 mm2
were analyzed. These results suggested that sunitinb increased the
quantity of hollow vessels or at least their roundness.
Finally, for CA4P samples, we performed a direct comparison.
Given that half of our CA4P samples presented sulfo-biotin-
stained cell bodies before vessel identification (Figures 6C and 6D),
we divided the 8 CA4P stacks into 2 groups (n = 4), one presenting
stained cell bodies and one presenting normal vessel staining.
Figure 6E shows the results obtained by comparing the
skeletonized vessels from these groups; the plot displays similar
curves and comparable values for percent volume and spatial
distribution. All together these results proved that the stained cell
bodies observed in greyscale images were correctly excluded from
binary images, minimizing the presence of artifacts in CA4P
samples. In addition, the similar shape of the curves in Figure 6E
excluded also the potential misclassification of vessels due to
artificially increased cross-sectional areas.
Discussion
In this work, we report the development of an approach used to
characterize tumor vascular networks according to microvessel
length, distribution and caliber. This analysis was restricted to
perinecrotic microvessels with a maximum approximate cross-
sectional area of 75 mm2 (about 10 mm in diameter for cylindrical
vessels), which enabled the characterization of different qualitative
and quantitative effects of antiangiogenic or antivascular drugs on
human tumor xenografts.
Unlike other efforts that have addressed the morphological
features of vascular trees [11,12,13] or their underlying physical
characteristics [14], our approach attempted to identify changes in
the vascular bed related to the arrangement of its small capillaries.
Two lines of thought prompted us to focus on these structures.
First, the presence of a microvessel in a given location reflects the
possibility for that tissutal environment to produce or maintain a
vessel of that caliber. Thus, by utilizing a tumor model in which
microvessels are evenly distributed throughout the tissue, we
sought to use these microvessels as probes to detect even small
changes in tumor vascularization. Second, small microvessels, as
compared to larger vessels, are fundamental to the oxygen and
nutrient distribution throughout the tissue [18], which suggests
that we should be able to correlate changes at this level with
changes in tissue viability.
In the course of our analysis, we observed the existence of a
relationship between vessel quantity and dispersion when consid-
Figure 4. Z-projection plot of untreated KMS-11 tumor nodules
analyzed in terms of staining amount and dispersion. Spatial
dispersion is expressed in terms of normalized volumetric Halo values
(nHv). Panel A. Symbols identify 8 different samples containing vessels
that were classified according to cross-section from the 21 classes listed
in Table 1. Identical symbols refer to results obtained from the same
sample and are shown connected with a line to demonstrate their
relationship. The large black line connects the medians obtained from
all the classes of samples. Panel B. Open and closed diamonds, triangles
and circles represent median values from the same 8 samples shown in
A, which contained vessels that were classified according to the first set
of classes reported in Table 1. Crosses represent median values after
vessel classification according to all of the 21 classes (identical to the
black curve in panel A). For the black symbols, horizontal and vertical
bars mark the IQR 50 (25–75%) of the samples.
doi:10.1371/journal.pone.0059691.g004
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ering vessels of different calibers. Given that the data from each
vessel class concur in regards to the dynamic balance between
vessel formation and loss at a given time in a given tissue location,
the meaning of this relationship appears related to the efficiency of
vascularization of the tissue, i.e., the ability to sustain the growth of
vessels from initial sprouts into functional capillaries. Thus,
following treatment with sorafenib or sunitinib, changes in the
ratio between ultrathin, immature stalks and RBC-conveying
capillaries highlighted the expected blockade of tumor angiogen-
esis.
Concerns can be expressed about the determination of vessel
dimensions following our approach and really several factors
contribute to spoil a precise measurement of the cross-sectional
area of the vessels. In spite that our samples were analyzed by
optical sectioning of a thick slice, we cannot rule out alterations
due to tissue shrinkage in the phase of sample preparation. In this
respect, other methods such as synchrotron radiation-based micro
computed tomography (SRmCT) [37] both in absorption [38] and
phase contrast modes [39] can provide high-resolution imaging of
3D vascular networks. Moreover, phase contrast SRmCT has been
recently shown to minimize sample alterations not only avoiding
sectioning and shrinkage but also bypassing the use of contrast or
casting agents needed in absorption mCT [39]. Thus, SRmCT
provides advantages over confocal analysis in the trustworthy
determination of 3D vascular networks. Unfortunately, the need
for a synchrotron facility limits its overall availability.
Along with tissue shrinkage, measurement of vessel caliber by
projection on a Cartesian plane introduced an additional
uncertainty. According to vessels orientation, vessel calibers can
be underestimated, their real values being sometimes larger up to
1.41 times. Thus vessel calibers should be regarded only as
indicative values. This inaccuracy prevented us to derive
Figure 5. Effects of treatments on vessel quantification. Panels A to D. Color-coded renderings of vascular trees from untreated and treated
samples. Vessels are shown grouped according to their approximate cross-section area as small (1–5 mm2; cyan), medium (5–19 mm2; yellow) and
large (19–75 mm2; red) caliber vessels. A, untreated KMS-11 nodules; B, CA4P; C, sorafenib; D, sunitinib. Panel E. z-projection plot of all of the 24
filtered stacks for the 4 treatments: black, untreated; red, CA4P; blue, sorafenib; green, sunitinb. Open and closed diamonds, triangles and circles refer,
in order, to classes of vessels of increasing caliber (see first set in Table 1). Spatial dispersion is expressed in terms of normalized volumetric Halo
values (nHv). The chart reports the medians and IQR 50, for both percent volume and spatial dispersion from 8 samples. Inside the same treatment,
points relative to vessels with increasing caliber are connected with a line of the appropriate color. Panel F is similar to E, although the data were
obtained after vessel skeletonization to remove the contribution of wall thickness.
doi:10.1371/journal.pone.0059691.g005
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meaningful diameter estimates given also that we were unable to
exclude changes in cross-section shapes due to drug-specific effects.
Despite these evident drawbacks, comparisons between treatments
were not affected by possible misclassification of the cross-sections
of vessels, given that all samples from different treatments were
classified by the same automatic procedure, treatments did not
selectively alter orientation and we analyzed large numbers of
samples.
Although both antiangiogenic treatments demonstrated similar
effects on skeletonized vessels, we were able to discriminate
between these effects based on the luminal volume of the vessels.
These differences were not due to a reduction in the level of sulfo-
biotin binding, but may have been linked to the specific effects of
the drugs [40,41,42,43]. In this respect, sunitinib is known to
destabilize vessels through the loss of pericyte coverage [44,45] as
a consequence of the inhibition of PDGFR signaling [41].
Although this loss has been correlated with the increase in
metastatic potential observed following sunitinib treatment [46],
the current study did not address this point, and further analyses
are required to link the differences we observed to any biological
effect.
The results of treatment with the antivascular drug CA4P
presented a reduction of RBC-conveying capillaries together with
an increased loss of thinner microvessels and ultrathin vessel
sprouts. However, these effects did not affect the shape and
orientation of the relationship between microvessels of different
caliber, which remained close to the control values, despite the
presence of large necrotic areas in the samples. Given that we were
Table 2. Significance of observed differences.
Projected vessel cross-section ( mm2)
S 1 – 2 2 – 5 5 – 9 9–19 19–37 37–75
C CP Sf C CP Sf C CP Sf C CP Sf C CP Sf C CP Sf
D Vol% CP *** *** *** ** ** *
Sf ** ns ** ns *** ns *** ns *** ** *** **
Sn ** ns ns *** ns ns *** * ns *** *** * *** *** ns *** *** *
D nHv 90%CP ** ** * * ns ns
Sf ** ns *** ns *** * *** * *** ** ** **
Sn ** ns ns *** ns ns *** * ns *** ** ns *** *** ns *** *** ns
Summary of statistical tests between Vol% (&delta Vol% - Welch’s t-test) and nHv 90% (&delta nH 90% - Wilcoxon rank test) for all of the classes of cross-sections
analyzed and shown in Figure 5. S, cross-section; C, controls; CP, CA4P; Sf, sorafenib; Sn, sunitinib. Significance: ns, not significant; *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0059691.t002
Figure 6. Exclusion of artifacts in CA4P-treated vessels. Input voxels were obtained after image thresholding by removing very small particles
(see Figure S2). Panel A. Search for CA4P-specific changes in the ratio between the amounts of input binary voxels and skeletonized voxels. Ratios are
reported on the Y axis. Symbols group results from vessels classified in the 6 bins of Table 1. Error bars refer to standard deviations, n = 8. Panel B.
Search for CA4P-specific changes in the ratio between total luminal volume and input voxels. Symbols and bars as in panel A. Error bars refer to
standard deviations, n = 8. Panels C and D. Representative images of CA4P-treated samples showing intracellular staining (C) or not (D). Panel E. z-
projection plot of CA4P-treated samples divided in 2 groups (n = 4) according to the presence of intracellular staining. Spatial dispersion is expressed
in terms of normalized volumetric Halo values (nHv). Dotted lines, samples with intracellular staining; solid lines, normal staining. The thin curves refer
to data from individual samples, whereas the large black curves connect medians for the percent volume and spatial dispersion.
doi:10.1371/journal.pone.0059691.g006
Quantifying Effects of Vascular-Targeted Therapies
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e59691
able to rule out the presence of artefacts due to altered sulfo-biotin
uptake by endothelial cells, these results demonstrate that the
antivascular action of CA4P did not affect the mechanisms of
tumor vessel formation.
Together, these results demonstrate that this study was able to
detail vascularization efficiency to an unprecedented extent, as
well as the effects induced by vascular-targeted therapies on tumor
vessels. In this respect, our efforts may provide an alternative
rationale for the multifaceted characterization of physio-patho-
logical vascular networks, at least at the microvessel level.
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